ASP0739 / Astellas, Riken - LARVOL DELTA

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (clinicaltrials.gov) - P1/2 | N=16 | Terminated | Sponsor: Astellas Pharma Global Development, Inc. | Completed ➔ Terminated; The comprehensive assessment of other studies indicated the lack of significant monotherapy activity, therefore, team decided to terminate the study.

Combination therapy • Metastases • Trial termination • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • CTAG1B • PD-L1 • SSX1

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (clinicaltrials.gov) - P1/2 | N=16 | Completed | Sponsor: Astellas Pharma Global Development, Inc. | Active, not recruiting ➔ Completed | N=339 ➔ 16 | Trial completion date: Jul 2024 ➔ May 2023 | Trial primary completion date: Jul 2024 ➔ May 2023

Combination therapy • Enrollment change • Metastases • Trial completion • Trial completion date • Trial primary completion date • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • CTAG1B • PD-L1 • SSX1

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (clinicaltrials.gov) - P1/2 | N=339 | Active, not recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Trial completion date: Jan 2028 ➔ Jul 2024 | Trial primary completion date: Jan 2026 ➔ Jul 2024

Combination therapy • Metastases • Trial completion date • Trial primary completion date • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • CTAG1B • PD-L1 • SSX1

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (clinicaltrials.gov) - P1/2 | N=339 | Active, not recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Recruiting ➔ Active, not recruiting

Combination therapy • Enrollment closed • Metastases • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • CTAG1B • PD-L1 • SSX1

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (clinicaltrials.gov) - P1/2; N=339; Recruiting; Sponsor: Astellas Pharma Global Development, Inc.; Initiation date: Oct 2021 ➔ Jan 2022

Clinical • Combination therapy • Trial initiation date • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • CTAG1B • PD-L1 • SSX1

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (clinicaltrials.gov) - P1/2; N=339; Recruiting; Sponsor: Astellas Pharma Global Development, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Combination therapy • Enrollment open • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • CTAG1B • PD-L1 • SSX1

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (clinicaltrials.gov) - P1/2; N=339; Not yet recruiting; Sponsor: Astellas Pharma Global Development, Inc.; Trial primary completion date: Jul 2024 ➔ Jan 2026

Clinical • Combination therapy • Trial primary completion date • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • CTAG1B • PD-L1 • SSX1